Tenderwize
Zurück zur Suche

Pharmaceutical products with active substance Filgotinib (ATC: L04AF04)

AOK Sachsen - Anhalt·Magdeburg, Germany·Deadline Jan 30, 2027 · 157 days left·Open·Supplies
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Arzneimittel mit dem Wirkstoff Filgotinib (ATC: L04AF04)

50/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Warum diese Bewertung?

Chance

50 / 100

Komplexität

20 / 100

Risikofaktoren

No guarantee of sales volumes; discounts may not lead to significant revenue.

Contracts may be terminated early if exclusive contracts are tendered. The notice states that this is not a public proc...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration 2 YEAR
  • Non-exclusive discount agreements for pharmaceutical products with active ingredient Filgotinib (ATC: L04AF04)
  • Open-house model with continuous enrollment
Vollständige Zusammenfassung anzeigen

This is an 'open-house' model for non-exclusive discount agreements on pharmaceutical products containing the active ingredient Filgotinib (ATC: L04AF04). The buyer is AOK Sachsen-Anhalt. Any qualified pharmaceutical company can join at any time under the same conditions. The contract duration is a maximum of 24 months, ending on 31 March 2027. The buyer explicitly states this is not a public procurement under EU Directive 2014/24/EU or German procurement law (GWB). No estimated value is provided. The notice includes some inconsistencies: structured data indicates no electronic submission, while the XML notice allows electronic submission via email with a qualified electronic signature; structured data marks it as EU-funded, but XML indicates no EU funds.

Risiken

No guarantee of sales volumes; discounts may not lead to significant revenue.

Contracts may be terminated early if exclusive contracts are tendered. The notice states that this is not a public proc...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Must be a pharmaceutical company or a consortium of pharmaceutical companies
  • Open-house model: no exclusivity, no individual negotiations

Administrative

  • Must request and submit fully completed and signed participation documents

Zuschlagskriterien

Lot 1

No specific award criteria; any qualified participant is accepted.

Auftraggeber

Ort

Magdeburg, DEU

Auftraggeberprofil

Profil öffnen

Kennung

DE258393558

Tätigkeit

Health

Lose (1)

LOT-0001

Pharmaceutical products with active substance Filgotinib (ATC: L04AF04)

Non-exclusive discount agreement for finished medicinal products containing Filgotinib (ATC L04AF04). Open to all interested pharmaceutical companies that meet participation requirements. No exclusivity, no individual negotiations. Contract start as early as 1 April 2025, maximum 24 months, ending 31 March 2027. The buyer reserves the right to terminate these agreements if exclusive contracts are tendered later.

SuppliesEU fundedElectronic submission

Ort

DEE03, Germany

Dauer

2 YEAR

Kategorie

Pharmaceutical products

Zuschlagskriterien

No specific award criteria; any qualified participant is accepted.

Vergabedetails

Veröffentlichungsdatum
18 Feb 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
110003-2025

Dokumente (1)

Ähnliche Ausschreibungen